Ibudilast Appears to Slow Brain Atrophy Progression in MS

In phase 2 randomized trial, 2.5ml less brain-tissue loss with ibudilast than with placebo over 96 weeks.
In phase 2 randomized trial, 2.5ml less brain-tissue loss with ibudilast than with placebo over 96 weeks.

HealthDay News — In patients with progressive multiple sclerosis, slower progression of brain atrophy was seen with ibudilast vs placebo, according to a phase 2 trial published in the August 30 issue of the New England Journal of Medicine.

Robert J. Fox, MD, from the Cleveland Clinic, and colleagues conducted a phase 2 trial in which patients with primary or secondary progressive multiple sclerosis were randomized to ≤100mg daily oral ibudilast (129 participants) or placebo (126 participants) for 96 weeks. A total of 53 percent of the patients in the ibudilast group and 52 percent of those in the placebo group had primary progressive disease, while the others had secondary progressive disease. 

Related Articles

The researchers found that the rate of change in the brain parenchymal fraction was −0.001 per year with ibudilast and −0.0019 per year with placebo, which represents approximately 2.5ml less brain-tissue loss with ibudilast over the study period. Adverse events with ibudilast included gastrointestinal symptoms, headache, and depression.

"Further trials are needed to identify whether the effect on brain atrophy is reproducible and is associated with slowed progression of neurologic disability," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including MediciNova, which manufactures ibudilast and provided funding for the study.

Abstract/Full Text (subscription or payment may be required)